What's new? Log in Free sign up

Exicure (XCUR)

Company Profile

Company profile

Ticker

XCUR

Exchange

Website

www.exicuretx.com

CEO

Mr. Paul Kang

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Max-1 Acquisition Corp

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Exicure Operating Company ...

XCUR stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Financial Statements and Exhibits

Entry into a Material Definitive Agreement

Departure of Directors or Certain Officers

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Entry into a Material Definitive Agreement

Definitive proxy

2 Dec 24

Departure of Directors or Certain Officers

Latest ownership filings

View all

Initial statement of insider ownership

HiTron Systems Inc.

Initial statement of insider ownership

Change in insider ownership

Financial summary

Financial statements Chart XCUR financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	951.00 k	951.00 k	951.00 k	951.00 k	951.00 k	951.00 k
Cash burn (monthly)	149.67 k	97.58 k	857.33 k	511.75 k	149.67 k	240.08 k
Cash used (since last report)	603.19 k	393.29 k	3.46 mm	2.06 mm	603.19 k	967.60 k
Cash remaining	347.81 k	557.71 k	-2.50 mm	-1.11 mm	347.81 k	-16.60 k
Runway (months of cash)	2.3	5.7	-2.9	-2.2	2.3	-0.1

Beta Read what these cash burn values mean

Financial data from Exicure earnings reports.

Institutional ownership, Q2 2024

XCUR institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	16	21	-23.8%
Opened positions	1	19	-94.7%
Closed positions	6	0	NEW
Increased positions	2	0	NEW
Reduced positions	4	1	+300.0%

13F shares	Current	Prev Q	Change
Total value	156.69 mm	285.76 mm	-45.2%
Total shares	8.38 mm	8.48 mm	-1.1%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Gates Ventures	4.84 mm	$1.17 mm	0.0%
CBI USA	3.06 mm	$1.01 mm	0.0%
CG The Carlyle Group Inc.	281.64 k	$88.77 mm	0.0%
Geode Capital Management	56.52 k	$18.54 mm	0.0%
Susquehanna International	46.00 k	$15.09 mm	NEW
Vanguard	40.09 k	$12.83 mm	0.0%
UBS UBS	17.31 k	$5.54 mm	+845.4%
Renaissance Technologies	14.90 k	$4.77 mm	-77.3%
Millennium Management	12.03 k	$3.95 mm	-65.4%
Tower Research Capital	7.18 k	$2.30 mm	+2.1%

Largest transactions	Shares	Bought/sold	Change
Renaissance Technologies	14.90 k	-50.70 k	-77.3%
Susquehanna International	46.00 k	+46.00 k	NEW
Virtu Financial	0.00	-27.04 k	EXIT
Millennium Management	12.03 k	-22.77 k	-65.4%
Two Sigma Securities	0.00	-22.70 k	EXIT
Citadel Advisors	0.00	-18.16 k	EXIT
UBS UBS	17.31 k	+15.48 k	+845.4%
BAC Bank of America	63.00	-12.74 k	-99.5%
Lazard Asset Management	0.00	-1.48 k	EXIT
Tower Research Capital	7.18 k	+151.00	+2.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

XCUR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Nov 24	Josh Miller	Common Stock	Payment of exercise	Dispose F	No	No	2.9	7	20.30	342

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Exicure Enters Share Purchase Agreement With GPCR Therapeutics

The Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation. The transactions contemplated under the Share Purchase Agreement closed

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket

Press releases

From Benzinga Pro

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. (NASDAQ:XCUR, "the Company", "Exicure")), today announced that on January 19, 2025, Exicure Inc. ("the Company") entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Exicure, Inc. (NASDAQ:XCUR, "Exicure", "the Company")), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. ("GPCR Therapeutics") on December 24, 2024, aimed at the acquisition

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. (NASDAQ:XCUR, "the Company", "Exicure")), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17,

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.